Susan P Perrine

Summary

Publications

  1. ncbi Evaluation of safety and pharmacokinetics of sodium 2,2 dimethylbutyrate, a novel short chain fatty acid derivative, in a phase 1, double-blind, placebo-controlled, single-dose, and repeat-dose studies in healthy volunteers
    Susan P Perrine
    HemaQuest Pharmaceuticals, Inc, Boston, MA 02110, USA
    J Clin Pharmacol 51:1186-94. 2011
  2. ncbi Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents
    Sajal K Ghosh
    Cancer Center, Boston University School of Medicine, 72 East Concord Street, Boston, MA 02118, USA
    Blood 119:1008-17. 2012
  3. ncbi Erythroid Kruppel-like factor (EKLF) is recruited to the gamma-globin gene promoter as a co-activator and is required for gamma-globin gene induction by short-chain fatty acid derivatives
    Susan P Perrine
    Cancer Center, Boston University School of Medicine, Boston, MA 02118, USA
    Eur J Haematol 82:466-76. 2009
  4. ncbi Short-chain fatty acids induce gamma-globin gene expression by displacement of a HDAC3-NCoR repressor complex
    Rishikesh Mankidy
    Gene Regulation Laboratories, Inc, Newton, MA, USA
    Blood 108:3179-86. 2006
  5. ncbi Fetal globin gene inducers: novel agents and new potential
    Susan P Perrine
    Cancer Center and Hemoglobinopathy Thalassemia Research Unit, Department of Medicine, Pediatrics, Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, Massachusetts, USA
    Ann N Y Acad Sci 1202:158-64. 2010
  6. ncbi Induction of fetal globin in beta-thalassemia: Cellular obstacles and molecular progress
    Susan P Perrine
    Hemoglobinopathy Thalassemia Research Unit, Boston University School of Medicine, 80 E Concord St, L 908, Boston, MA 02118, USA
    Ann N Y Acad Sci 1054:257-65. 2005
  7. ncbi A randomized phase II trial of Arginine Butyrate with standard local therapy in refractory sickle cell leg ulcers
    Lillian McMahon
    Cancer Center and Hemoglobinopathy Thalassemia Research Unit, Boston University School of Medicine, Boston, MA 02118, USA
    Br J Haematol 151:516-24. 2010
  8. ncbi Identification of novel small-molecule inducers of fetal hemoglobin using pharmacophore and 'PSEUDO' receptor models
    Regine Bohacek
    Boston De Novo Design, 50 Commonwealth Ave, Boston, MA 02116, USA
    Chem Biol Drug Des 67:318-28. 2006
  9. ncbi Short, discontinuous exposure to butyrate effectively sensitizes latently EBV-infected lymphoma cells to nucleoside analogue antiviral agents
    Sajal K Ghosh
    Cancer Research Center, Boston University School of Medicine, 715 Albany Street, K701, Boston, MA 02118, USA
    Blood Cells Mol Dis 38:57-65. 2007
  10. ncbi Histone deacetylase inhibitors reverse CpG methylation by regulating DNMT1 through ERK signaling
    Sibaji Sarkar
    Cancer Center, Boston University School of Medicine, Boston, MA 02118, USA
    Anticancer Res 31:2723-32. 2011

Collaborators

Detail Information

Publications15

  1. ncbi Evaluation of safety and pharmacokinetics of sodium 2,2 dimethylbutyrate, a novel short chain fatty acid derivative, in a phase 1, double-blind, placebo-controlled, single-dose, and repeat-dose studies in healthy volunteers
    Susan P Perrine
    HemaQuest Pharmaceuticals, Inc, Boston, MA 02110, USA
    J Clin Pharmacol 51:1186-94. 2011
    ..The favorable pharmacokinetics (PK) profiles and safety findings indicate that SDMB warrants further investigation for treatment of anemic subjects with beta hemoglobinopathies...
  2. ncbi Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents
    Sajal K Ghosh
    Cancer Center, Boston University School of Medicine, 72 East Concord Street, Boston, MA 02118, USA
    Blood 119:1008-17. 2012
    ..The effectiveness and potency of these HDAC inhibitors make them potentially applicable as sensitizers to antivirals for the treatment of EBV-associated lymphomas...
  3. ncbi Erythroid Kruppel-like factor (EKLF) is recruited to the gamma-globin gene promoter as a co-activator and is required for gamma-globin gene induction by short-chain fatty acid derivatives
    Susan P Perrine
    Cancer Center, Boston University School of Medicine, Boston, MA 02118, USA
    Eur J Haematol 82:466-76. 2009
    ..We sought to determine if EKLF is also required for activation of the gamma-globin gene by short-chain fatty acid (SCFA) derivatives, which are now entering clinical trials...
  4. ncbi Short-chain fatty acids induce gamma-globin gene expression by displacement of a HDAC3-NCoR repressor complex
    Rishikesh Mankidy
    Gene Regulation Laboratories, Inc, Newton, MA, USA
    Blood 108:3179-86. 2006
    ..These studies demonstrate new dynamic alterations in transcriptional regulatory complexes associated with SCFAD-induced activation of the gamma-globin gene and provide a specific molecular target for potential therapeutic intervention...
  5. ncbi Fetal globin gene inducers: novel agents and new potential
    Susan P Perrine
    Cancer Center and Hemoglobinopathy Thalassemia Research Unit, Department of Medicine, Pediatrics, Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, Massachusetts, USA
    Ann N Y Acad Sci 1202:158-64. 2010
    ..These refinements offer renewed potential to apply fetal globin induction as a treatment approach in patient-friendly regimens that can be used worldwide...
  6. ncbi Induction of fetal globin in beta-thalassemia: Cellular obstacles and molecular progress
    Susan P Perrine
    Hemoglobinopathy Thalassemia Research Unit, Boston University School of Medicine, 80 E Concord St, L 908, Boston, MA 02118, USA
    Ann N Y Acad Sci 1054:257-65. 2005
    ..Both approaches now offer excellent potential for tolerable, definitive treatment of beta-thalassemia...
  7. ncbi A randomized phase II trial of Arginine Butyrate with standard local therapy in refractory sickle cell leg ulcers
    Lillian McMahon
    Cancer Center and Hemoglobinopathy Thalassemia Research Unit, Boston University School of Medicine, Boston, MA 02118, USA
    Br J Haematol 151:516-24. 2010
    ..These findings strongly suggest that Arginine Butyrate merits further evaluation for the treatment of refractory sickle cell leg ulcers in larger trials...
  8. ncbi Identification of novel small-molecule inducers of fetal hemoglobin using pharmacophore and 'PSEUDO' receptor models
    Regine Bohacek
    Boston De Novo Design, 50 Commonwealth Ave, Boston, MA 02116, USA
    Chem Biol Drug Des 67:318-28. 2006
    ....
  9. ncbi Short, discontinuous exposure to butyrate effectively sensitizes latently EBV-infected lymphoma cells to nucleoside analogue antiviral agents
    Sajal K Ghosh
    Cancer Research Center, Boston University School of Medicine, 715 Albany Street, K701, Boston, MA 02118, USA
    Blood Cells Mol Dis 38:57-65. 2007
    ....
  10. ncbi Histone deacetylase inhibitors reverse CpG methylation by regulating DNMT1 through ERK signaling
    Sibaji Sarkar
    Cancer Center, Boston University School of Medicine, Boston, MA 02118, USA
    Anticancer Res 31:2723-32. 2011
    ..These results demonstrate that HDACs regulate gene methylation, in addition to the established and reciprocal ability of CpG methylation to recruit HDACs to repress transcription...
  11. ncbi Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential
    Susan P Perrine
    Hemoglobinopathy Thalassemia Research Unit, Boston University School of Medicine, Boston, Massachusetts, USA
    Pediatr Ann 37:339-46. 2008
    ..Development of this therapeutic avenue will require close collaboration among treating and academic physicians, families and patients, funding agencies, and researchers...
  12. ncbi Enhancement of growth and survival and alterations in Bcl-family proteins in beta-thalassemic erythroid progenitors by novel short-chain fatty acid derivatives
    Serguei Castaneda
    Hemoglobinopathy-Thalassemia Research Unit and Cancer Research Center, Boston University School of Medicine, 715 Albany Street, L-908, Boston, MA 02118, USA
    Blood Cells Mol Dis 35:217-26. 2005
    ....
  13. ncbi Advances in Virus-Directed Therapeutics against Epstein-Barr Virus-Associated Malignancies
    Sajal K Ghosh
    Cancer Center, Boston University School of Medicine, Boston, MA 02118, USA
    Adv Virol 2012:509296. 2012
    ..In this paper we provide a brief account of new virus-targeted therapeutic approaches against EBV-associated malignancies...
  14. ncbi A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies
    Susan P Perrine
    Cancer Research Center, Boston University School of Medicine, Boston, MA 02118, USA
    Blood 109:2571-8. 2007
    ..The combination of arginine butyrate and ganciclovir was reasonably well-tolerated and appears to have significant biologic activity in vivo in EBV(+) lymphoid malignancies which are refractory to other regimens...
  15. ncbi Alpha-lipoic acid induces p27Kip-dependent cell cycle arrest in non-transformed cell lines and apoptosis in tumor cell lines
    Karyn van de Mark
    Cancer Research Center, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    J Cell Physiol 194:325-40. 2003
    ..The differential selectivity of the pro-apoptotic effects of alpha-lipoic acid for transformed cells supports its potential use in the treatment of neoplastic disorders...